April 8 (Reuters) - Walgreens, which is in the process of being taken private by Sycamore Partners, beat Wall Street estimates for quarterly profit as the pharmacy chain operator benefited from a turnaround effort that included closing underperforming stores.
On an adjusted basis, Walgreens earned 63 cents per share in the second quarter, compared with the average analyst estimate of 53 cents, according to data compiled by LSEG.
The company said on Tuesday it is withdrawing its fiscal 2025 forecast, pending the deal close.
Walgreens in March agreed to be taken private by PE firm Sycamore Partners for $10 billion, closing out nearly a century of trading on public markets for the U.S. pharmacy giant. The company expects the transaction to close in the fourth quarter of this year.
Sycamore specializes in retail and consumer investments, and has a track record of acquiring distressed retailers for profit including brands such as Staples, Talbots and Nine West.
Walgreens' retail business has struggled with inflation-driven weakness in consumer spending and its pharmacy operation has faced low reimbursement rates for filing prescriptions.
Its U.S. retail pharmacy unit reported sales of $30.38 billion for the quarter ended February 28, beating estimates of $29.67 billion.
The pharmacy retailer appointed healthcare industry veteran Tim Wentworth as CEO in 2023 after former top boss Rosalind Brewer abruptly stepped down.
Since taking on the reins, Wentworth unveiled a series of changes including the removal of multiple mid-level executives, a $1 billion cost-cutting exercise and plans to close 1,200 stores.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.